


This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Currently Amended) A method ~~of~~ for treating a human patient suffering from dry eye, comprising:

administering to the patient an ophthalmic composition comprising from about 0.01%  
to about 0.1% of FK506 represented by the following structure



wherein prior to treatment said patient has a Schirmer score of less than or equal to seven millimeters per five minutes, said method comprising administering to the patient an ophthalmic composition containing a macrolide compound.

2. (Currently Amended) A The method according to claim 1, wherein prior to treatment said patient has a Schirmer score of less than or equal to five millimeters per five minutes.

3. (Canceled)

4. (Currently Amended) A The method according to claim ~~[[3]]~~ 1, wherein said ophthalmic composition contains from about ~~0.03~~ 0.01% to about 0.06% of ~~said macrolide compound~~ FK506.

5. (Currently Amended) A The method according to claim 4, wherein said ophthalmic composition contains about 0.03% of ~~said macrolide compound~~ FK506.

6. (Canceled)

7. (Currently Amended) A The method according to claim 1, wherein said ophthalmic composition is an eye drop.

8. (Currently Amended) A The method according to claim 7, wherein said eye drop further ~~contains~~ comprises a polyvinyl alcohol.

9. (Currently Amended) A The method according to claim 7, wherein said eye drop contains about 0.03% of ~~said macrolide compound~~ FK506.

10. (Currently Amended) A The method according to claim 7, wherein said eye drop is administered from about one to about four times per day.


11-12. (Canceled)

13. (Currently Amended) A The method according to claim 1 or 2, wherein prior to treatment said patient also has a superficial punctate keratitis (SPK) score of at least two.

14. (Currently Amended) A The method according to claim 13, wherein prior to treatment said patient also has a superficial punctate keratitis (SPK) score of at least three.

15. (Currently Amended) A method ~~of~~ for treating a human patient suffering from dry eye, comprising:

administering to the patient an ophthalmic composition containing from about 0.01% to about 0.1% of FK506 represented by the following structure




\_\_\_\_\_;

wherein prior to treatment said patient has a superficial punctate keratitis (SPK) score of at least two, ~~said method comprising administering to the patient an ophthalmic composition containing a macrolide compound.~~

16. (Currently Amended) A method of treating a human patient suffering from an ocular surface damage associated with dry eye, ~~wherein prior to treatment the patient has a superficial punctate keratitis (SPK) score of at least two~~, said method comprising:

administering to the patient an ophthalmic composition containing ~~a macrolide compound~~ from about 0.01% to about 0.1% of FK506 represented by the following structure




\_\_\_\_\_;

wherein prior to treatment the patient has a superficial punctate keratitis (SPK) score of at least two.

17. (Currently Amended) A method of treating a human patient suffering from an ocular discomfort associated with dry eye, ~~wherein prior to treatment the patient has a Schirmer score of less than or equal to seven millimeters per five minutes~~, said method comprising:

administering to the patient an ophthalmic composition containing ~~a macrolide compound~~ from about 0.01% to about 0.1% of FK506 represented by the following structure




wherein prior to treatment the patient has a Schirmer score of less than or equal to seven millimeters per five minutes.

18. (Currently Amended) A method of treating a human patient suffering from an ocular discomfort associated with dry eye, ~~wherein prior to treatment the patient has a superficial punctate keratitis (SPK) score of at least two,~~ said method comprising:

administering to the patient an ophthalmic composition containing ~~a macrolide compound~~


from about 0.01% to about 0.1% of FK506 represented by the following structure



wherein prior to treatment the patient has a superficial punctate keratitis (SPK) score of at least two.

19. (Currently Amended) A method of treating a human patient suffering from an ocular surface damage associated with dry eye, ~~wherein prior to treatment the patient has a Schirmer score of less than or equal to seven millimeters per five minutes~~, said method comprising:

administering to the patient an ophthalmic composition containing ~~a macrolide compound~~ from about 0.01% to about 0.1% of FK506 represented by the following structure



23. (New) A method according to claim 18, wherein said ophthalmic composition contains from about 0.01% to about 0.06% of FK506.

Application No.: 10/758,260

Reply to the Office Action dated: March 9, 2005

24. (New) A method according to claim 19, wherein said ophthalmic composition contains from about 0.01% to about 0.06% of FK506.



Application No.: 10/758,260

Reply to the Office Action dated: March 9, 2005

**BASIS FOR THE AMENDMENT**

Claims 3, 6, 11, 12 have been canceled.

The remaining claims have been limited as supported, for example, by Claim 12 as originally filed.

New Claims 20-24 have been added as supported by the specification.

No new matter is believed to have been added by entry of this amendment. Entry and favorable reconsideration are respectfully requested.

Upon entry of this amendment Claims 1, 2, 4, 5, 7-10, and 13-24 will now be active in this application.